Cape Investment Advisory, Inc. Alnylam Pharmaceuticals, Inc. Transaction History
Cape Investment Advisory, Inc.
- $251 Billion
- Q1 2025
A detailed history of Cape Investment Advisory, Inc. transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Cape Investment Advisory, Inc. holds 90 shares of ALNY stock, worth $29,871. This represents 0.01% of its overall portfolio holdings.
Number of Shares
90
Previous 90
-0.0%
Holding current value
$29,871
Previous $21.2 Million
14.75%
% of portfolio
0.01%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding ALNY
# of Institutions
721Shares Held
111MCall Options Held
978KPut Options Held
881K-
Capital World Investors Los Angeles, CA16.7MShares$5.56 Billion0.76% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.1MShares$4.33 Billion0.07% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$3.17 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.15MShares$2.37 Billion0.44% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.42MShares$1.47 Billion0.79% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $40.8B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...